Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$18.9M Sell
75,067
-605
-0.8% -$130K 2.84% 3
2026
Q1
$16.5M Sell
75,672
-540
-0.7% -$120K 2.57% 5
2025
Q4
$17.4M Sell
76,212
-6,035
-7% -$1.37M 2.82% 4
2025
Q3
$19M Buy
82,247
+945
+1% +$192K 3.13% 4
2025
Q2
$15.1M Buy
81,302
+2,163
+3% +$402K 2.7% 4
2025
Q1
$16.6M Buy
79,139
+1,193
+2% +$232K 3.02% 3
2024
Q4
$13.9M Buy
77,946
+652
+0.8% +$120K 2.61% 4
2024
Q3
$15.3M Buy
77,294
+295
+0.4% +$55.1K 2.77% 3
2024
Q2
$13.2M Sell
76,999
-397
-0.5% -$65.8K 2.66% 4
2024
Q1
$14.1M Sell
77,396
-816
-1% -$141K 2.8% 3
2023
Q4
$12.1M Sell
78,212
-1,011
-1% -$147K 2.6% 3
2023
Q3
$11.8M Buy
79,223
+908
+1% +$133K 2.74% 3
2023
Q2
$10.6M Buy
78,315
+3,071
+4% +$450K 2.32% 7
2023
Q1
$12M Sell
75,244
-3,007
-4% -$460K 2.62% 3
2022
Q4
$12.6M Sell
78,251
-2,176
-3% -$334K 2.72% 4
2022
Q3
$10.8M Sell
80,427
-3,687
-4% -$529K 2.67% 4
2022
Q2
$12.9M Buy
+84,114
New +$12.9M 3% 4

Other funds holding ABBV

Advocate Group's ABBV Position: Q2 2026 in Review

Advocate Group reduced its AbbVie (ABBV) stake by 0.8% in Q2 2026, selling an estimated $130K and leaving 75,067 shares worth $18.9M. The position accounts for 2.84% of the portfolio, ranked #3.

Advocate Group first reported a position in ABBV in Q2 2022 and has held it in 17 quarters since. The position peaked at $19M in Q3 2025. 2,121 funds tracked by Wall St. Rank hold ABBV as of Q2 2026.

  • Advocate Group held 75,067 shares of AbbVie worth $18.9M as of Q2 2026.
  • Advocate Group sold 605 AbbVie shares in Q2 2026, an estimated $130K.
  • AbbVie made up 2.84% of Advocate Group's portfolio in Q2 2026, its #3 holding.
  • Advocate Group first reported a position in AbbVie in Q2 2022 and has held it in 17 quarters since.
  • Advocate Group's AbbVie position peaked at $19M in Q3 2025.
  • 2,121 funds tracked by Wall St. Rank held AbbVie as of Q2 2026.

Based on Advocate Group's 13F filing for Q2 2026, filed 17 Jul 2026.